Back to news

RenovoRx Appoints Interventional Oncology Medtech Leader Richard Stark to its Board of Directors

Globe Newswire•19/11/2026•08:30 ET
0

Key Highlights

  • ➤Richard Stark appointed to RenovoRx’s Board of Directors
  • ➤Stark has advised RenovoRx’s commercial team since late 2024
  • ➤RenovoRx completed Phase III TIGeR-PaC enrollment in August 2026
  • ➤Initial TIGeR-PaC topline data expected in second half of 2027

Expert Statements

Shaun Bagai, Chief Executive Officer of RenovoRx

“We are pleased to welcome Rick to our Board of Directors. Beyond his decades of experience in medtech sales and marketing, Rick has been instrumental in building the infrastructure that is accelerating physician adoption of RenovoCath in interventional oncology, and his insight sharpened our commercial approach at a critical juncture. As our market penetration across cancer centers deepens, his boardroom perspective will be important in continuing to shape our commercial strategy and guiding how we scale.”

Richard A. Stark, Chief Executive Officer of Innoblative Designs, Inc. and newly appointed RenovoRx Board member

“I have spent my career working with oncologists and other physicians to adopt technologies that deliver therapy with greater precision, and I believe RenovoRx is well positioned with RenovoCath at the intersection of innovation and patient impact. Having worked as an advisor to the commercial team for nearly two years, I have seen the TAMP platform’s strength firsthand, and I am excited to continue to contribute my experience as a Board member as the Company builds on its innovative approach to targeted therapeutic delivery for patients with difficult-to-treat solid tumors.”

MOUNTAIN VIEW, Calif., Nov. 19, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company commercializing RenovoCath(®), a patented, FDA-cleared drug-delivery device, and evaluating a novel targeted oncology drug-device product candidate, today announced the appointment of Richard A. Stark, Chief Executive Officer of Innoblative Designs, Inc., to the Company’s Board of Directors.

Mr. Stark brings more than three decades of leadership experience in medical technology to the RenovoRx Board, with a focus on setting and executing commercialization strategies of interventional oncology medical technologies. He has advised RenovoRx since late 2024, helping its commercial team lay the foundation for the Company’s commercial efforts. He now brings his expertise and knowledge of the RenovoRx’s TAMP™ (Trans-Arterial Micro-Perfusion) platform, enabled by RenovoCath, to the Company’s Board as RenovoRx continues to gain traction in the market and physician adoption across U.S. cancer centers.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in